Sight Sciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.5%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$86Mnext fiscal year
FY EPS (est.)
-$0.76next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly19.7MTarget: 83000000 to 89000000
Interventional Glaucoma Segment Revenue Quarterly18.3MTarget: 77000000 to 81000000
Interventional Dry Eye Segment Revenue Quarterly1.4MTarget: 6000000 to 8000000
Gross Margin Quarterly86.0%Target: Maintain mid-to-high 80s
Watch Items
- Patent Litigation Judgment and AppealsTrigger: Final resolution of Alcon/Ivantis appeal on the $55.4 million damages and 10% ongoing Hydrus royaltiesAction: Monitor court filings and Alcon's appeal progress to assess cash inflow timing and potential balance sheet impact.
- Interventional Dry Eye Commercial ScalingTrigger: TearCare system commercial adoption and insurance coverage decisionsAction: Track sequential growth in active accounts and utilization rates of SmartLids to validate commercial traction.
- Cash Burn and Pathway to Cashflow BreakevenTrigger: Quarterly cash usage exceeding $7.0 millionAction: Evaluate operating expense discipline against the reaffirmed FY2026 adjusted operating expense guidance of $93.0 million to $96.0 million.
Research as of 19 Jun 2026